Cargando…

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel

BACKGROUND: BNT162b2 was shown to be 92% effective in preventing COVID-19. Prioritizing vaccine rollout, and achievement of herd immunity depend on SARS-CoV-2 transmission reduction. The vaccine's effect on infectivity is thus a critical priority. METHODS: Among all 9650 HCW of a large tertiary...

Descripción completa

Detalles Bibliográficos
Autores principales: Regev-Yochay, Gili, Amit, Sharon, Bergwerk, Moriah, Lipsitch, Marc, Leshem, Eyal, Kahn, Rebecca, Lustig, Yaniv, Cohen, Carmit, Doolman, Ram, Ziv, Arnona, Novikov, Ilya, Rubin, Carmit, Gimpelevich, Irena, Huppert, Amit, Rahav, Galia, Afek, Arnon, Kreiss, Yitshak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261633/
https://www.ncbi.nlm.nih.gov/pubmed/34250518
http://dx.doi.org/10.1016/j.lanepe.2021.100150
_version_ 1783719047932674048
author Regev-Yochay, Gili
Amit, Sharon
Bergwerk, Moriah
Lipsitch, Marc
Leshem, Eyal
Kahn, Rebecca
Lustig, Yaniv
Cohen, Carmit
Doolman, Ram
Ziv, Arnona
Novikov, Ilya
Rubin, Carmit
Gimpelevich, Irena
Huppert, Amit
Rahav, Galia
Afek, Arnon
Kreiss, Yitshak
author_facet Regev-Yochay, Gili
Amit, Sharon
Bergwerk, Moriah
Lipsitch, Marc
Leshem, Eyal
Kahn, Rebecca
Lustig, Yaniv
Cohen, Carmit
Doolman, Ram
Ziv, Arnona
Novikov, Ilya
Rubin, Carmit
Gimpelevich, Irena
Huppert, Amit
Rahav, Galia
Afek, Arnon
Kreiss, Yitshak
author_sort Regev-Yochay, Gili
collection PubMed
description BACKGROUND: BNT162b2 was shown to be 92% effective in preventing COVID-19. Prioritizing vaccine rollout, and achievement of herd immunity depend on SARS-CoV-2 transmission reduction. The vaccine's effect on infectivity is thus a critical priority. METHODS: Among all 9650 HCW of a large tertiary medical center in Israel, we calculated the prevalence of positive SARS-CoV-2 qRT-PCR cases with asymptomatic presentation, tested following known or presumed exposure and the infectious subset (N-gene-Ct-value<30) of these. Additionally, infection incidence rates were calculated for symptomatic cases and infectious (Ct<30) cases. Vaccine effectiveness within three months of vaccine rollout was measured as one minus the relative risk or rate ratio, respectively. To further assess infectiousness, we compared the mean Ct-value and the proportion of infections with a positive SARS-CoV-2 antigen test of vaccinated vs. unvaccinated. The correlation between IgG levels within the week before detection and Ct level was assessed. FINDINGS: Reduced prevalence among fully vaccinated HCW was observed for (i) infections detected due to exposure, with asymptomatic presentation (VE(i)=65.1%, 95%CI 45-79%), (ii) the presumed infectious (Ct<30) subset of these (VE(ii)=69.6%, 95%CI 43-84%) (iii) never-symptomatic infections (VE(iii)=72.3%, 95%CI 48-86%), and (iv) the presumed infectious (Ct<30) subset (VE(iv)=83.0%, 95%CI 51-94%). Incidence of (v) symptomatic and (vi) symptomatic-infectious cases was significantly lower among fully vaccinated vs. unvaccinated individuals (VE(v)= 89.7%, 95%CI 84-94%, VE(vi)=88.1%, 95%CI 80-95%). The mean Ct-value was significantly higher in vaccinated vs. unvaccinated (27.3±1.2 vs. 22.2±1.0, p<0.001) and the proportion of positive SARS-CoV-2 antigen tests was also significantly lower among vaccinated vs. unvaccinated PCR-positive HCW (80% vs. 31%, p<0.001). Lower infectivity was correlated with higher IgG concentrations (R=0.36, p=0.01). INTERPRETATION: These results suggest that BNT162b2 is moderately to highly effective in reducing infectivity, via preventing infection and through reducing viral shedding. FUNDING: Sheba Medical Center, Israel
format Online
Article
Text
id pubmed-8261633
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82616332021-07-07 Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel Regev-Yochay, Gili Amit, Sharon Bergwerk, Moriah Lipsitch, Marc Leshem, Eyal Kahn, Rebecca Lustig, Yaniv Cohen, Carmit Doolman, Ram Ziv, Arnona Novikov, Ilya Rubin, Carmit Gimpelevich, Irena Huppert, Amit Rahav, Galia Afek, Arnon Kreiss, Yitshak Lancet Reg Health Eur Research Paper BACKGROUND: BNT162b2 was shown to be 92% effective in preventing COVID-19. Prioritizing vaccine rollout, and achievement of herd immunity depend on SARS-CoV-2 transmission reduction. The vaccine's effect on infectivity is thus a critical priority. METHODS: Among all 9650 HCW of a large tertiary medical center in Israel, we calculated the prevalence of positive SARS-CoV-2 qRT-PCR cases with asymptomatic presentation, tested following known or presumed exposure and the infectious subset (N-gene-Ct-value<30) of these. Additionally, infection incidence rates were calculated for symptomatic cases and infectious (Ct<30) cases. Vaccine effectiveness within three months of vaccine rollout was measured as one minus the relative risk or rate ratio, respectively. To further assess infectiousness, we compared the mean Ct-value and the proportion of infections with a positive SARS-CoV-2 antigen test of vaccinated vs. unvaccinated. The correlation between IgG levels within the week before detection and Ct level was assessed. FINDINGS: Reduced prevalence among fully vaccinated HCW was observed for (i) infections detected due to exposure, with asymptomatic presentation (VE(i)=65.1%, 95%CI 45-79%), (ii) the presumed infectious (Ct<30) subset of these (VE(ii)=69.6%, 95%CI 43-84%) (iii) never-symptomatic infections (VE(iii)=72.3%, 95%CI 48-86%), and (iv) the presumed infectious (Ct<30) subset (VE(iv)=83.0%, 95%CI 51-94%). Incidence of (v) symptomatic and (vi) symptomatic-infectious cases was significantly lower among fully vaccinated vs. unvaccinated individuals (VE(v)= 89.7%, 95%CI 84-94%, VE(vi)=88.1%, 95%CI 80-95%). The mean Ct-value was significantly higher in vaccinated vs. unvaccinated (27.3±1.2 vs. 22.2±1.0, p<0.001) and the proportion of positive SARS-CoV-2 antigen tests was also significantly lower among vaccinated vs. unvaccinated PCR-positive HCW (80% vs. 31%, p<0.001). Lower infectivity was correlated with higher IgG concentrations (R=0.36, p=0.01). INTERPRETATION: These results suggest that BNT162b2 is moderately to highly effective in reducing infectivity, via preventing infection and through reducing viral shedding. FUNDING: Sheba Medical Center, Israel Elsevier 2021-07-07 /pmc/articles/PMC8261633/ /pubmed/34250518 http://dx.doi.org/10.1016/j.lanepe.2021.100150 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Regev-Yochay, Gili
Amit, Sharon
Bergwerk, Moriah
Lipsitch, Marc
Leshem, Eyal
Kahn, Rebecca
Lustig, Yaniv
Cohen, Carmit
Doolman, Ram
Ziv, Arnona
Novikov, Ilya
Rubin, Carmit
Gimpelevich, Irena
Huppert, Amit
Rahav, Galia
Afek, Arnon
Kreiss, Yitshak
Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
title Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
title_full Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
title_fullStr Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
title_full_unstemmed Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
title_short Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
title_sort decreased infectivity following bnt162b2 vaccination: a prospective cohort study in israel
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261633/
https://www.ncbi.nlm.nih.gov/pubmed/34250518
http://dx.doi.org/10.1016/j.lanepe.2021.100150
work_keys_str_mv AT regevyochaygili decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT amitsharon decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT bergwerkmoriah decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT lipsitchmarc decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT leshemeyal decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT kahnrebecca decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT lustigyaniv decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT cohencarmit decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT doolmanram decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT zivarnona decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT novikovilya decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT rubincarmit decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT gimpelevichirena decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT huppertamit decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT rahavgalia decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT afekarnon decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael
AT kreissyitshak decreasedinfectivityfollowingbnt162b2vaccinationaprospectivecohortstudyinisrael